The short answer
The KPV literature rests on three immortalised human cell lines and two chemically induced mouse colitis models. Each is a legitimate research tool with a specific and limited scope, and the distance between a nanomolar effect in a reporter assay and anything clinical is very large.
Key facts
- Epithelial lines used
- Caco2-BBE, HT29-Cl.19A
- Immune line used
- Jurkat, a human T-cell line
- What Caco-2 derives from
- Human colon adenocarcinoma
- Mouse colitis models used
- DSS and TNBS
- Tumorigenesis model used
- AOM/DSS
- Typical readout
- NF-kappaB luciferase reporter, cytokine mRNA and protein
- Reported in vitro active range
- Nanomolar
- Registered human trials of KPV
- None
Why this article exists in a category about a molecule
Every number anyone quotes about KPV comes from one of a small number of experimental systems, and the systems constrain what the numbers can mean far more tightly than the numbers themselves suggest. A reader who knows what Caco-2 is will read 'nanomolar anti-inflammatory activity' differently from one who does not. This is not scepticism about the work; the systems described here are standard, well-validated tools that were the correct choice for the questions asked. It is about matching the size of a claim to the system that produced it.
Caco-2 and HT29: intestinal epithelium, with caveats
Caco-2 is derived from a human colon adenocarcinoma. Grown to confluence and allowed to differentiate, it spontaneously develops many features of small-intestinal epithelium: polarised monolayers, tight junctions, brush-border enzymes and, relevantly here, peptide transporter expression. The BBE subclone used in this work was selected for brush-border expression. That makes it the standard model for intestinal absorption studies and a reasonable place to ask whether a transporter carries a substrate. It is also a cancer line, immortalised, grown without the microbiome, immune cells, mucus layer, blood supply or mechanical environment of a real intestine, and its transporter expression does not necessarily match a healthy person's. HT29-Cl.19A is a second colonic line used alongside it, which guards against a result being an artefact of one cell line. That is a useful control, because many studies do not bother.
Research material referenced
KPV 10mg, third-party HPLC tested
Jurkat: a leukaemic T-cell line
Jurkat cells are an immortalised human T-cell leukaemia line, used for decades because they are easy to grow and have well-characterised signalling. They are a legitimate tool for asking whether a compound affects a signalling pathway in a T cell. They are not primary human T cells, their signalling differs from primary cells in documented ways, and a result in Jurkat is a hypothesis about lymphocytes rather than a description of them.
What a luciferase reporter measures
An NF-kappaB luciferase reporter is a construct: a promoter containing NF-kappaB binding sites drives an enzyme whose activity is read as light. It is a fast, sensitive and quantitative way to ask whether a pathway's transcriptional output moved. It measures the construct, not the endogenous gene programme, and it can respond to things that affect the reporter without affecting the biology. This is why the 2008 KPV work is stronger than a reporter study alone. It added Western blot, real-time RT-PCR and ELISA, so the signal was followed from transcription factor activity through to secreted protein.
Why nanomolar in a dish is not a dose
A concentration in a culture well is set by the experimenter and held roughly constant. A concentration in an animal is the outcome of absorption, distribution, metabolism and excretion, varies continuously, and differs between tissues. Nanomolar activity says the molecule is potent against its target in that system; it says nothing about whether that concentration is reachable at the relevant tissue in a living organism, for how long, or at what cost elsewhere. Translating one into the other is the entire discipline of pharmacokinetics, and for KPV it has not been done in humans at all.
The mouse models, and the size of the remaining gap
Dextran sulfate sodium and trinitrobenzene sulfonic acid colitis are chemically induced injuries with different immunological characters (the first largely epithelial-barrier driven, the second more T-cell mediated), which is why using both, as the 2008 work did, is better than using one. Neither reproduces the cause or course of human inflammatory bowel disease. The AOM/DSS model used in the later knockout work induces tumours chemically on a background of chemical colitis. All three are tools for probing mechanism. The historical record of compounds that worked in rodent colitis models and then failed in people is long, and it is the main reason a result in these systems is a reason to keep looking rather than a conclusion.
Frequently asked questions
Is cell line work worthless then?
No. It is where mechanism gets established, and the KPV transport work is a good example of what it does well. The error is not doing the experiment; it is quoting its numbers as though they described a person.
Why use a cancer-derived line to model a healthy gut?
Because primary intestinal epithelial cells are difficult to obtain and do not survive long in culture. Caco-2 is the practical compromise the field settled on, and its limitations are well documented rather than hidden. Organoid systems now offer an alternative, and none of the KPV work described here used them.
What would it take to know whether KPV does anything in people?
A registered clinical trial with a defined population, a comparator, a pre-specified endpoint and an analysis plan. None exists. Until one does, everything on this subject is preclinical, and describing it otherwise would be false.
Does this apply to other compounds in this library?
To most of them, yes. Reading what system a number came from before reading the number itself is the single most useful habit for anyone working through a preclinical literature.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedDalmasso G et al., PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation - Gastroenterology 2008 (PMID 18061177)pubmed.ncbi.nlm.nih.gov
- PubMedViennois E et al., Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV - Cell Mol Gastroenterol Hepatol 2016 (PMID 27458604)pubmed.ncbi.nlm.nih.gov
- PubMedZeng M et al., Peptide Receptor-Targeted Fluorescent Probe: Visualization and Discrimination between Chronic and Acute Ulcerative Colitis - ACS Appl Mater Interfaces 2017 (PMID 28349696)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More KPV articles
- What Is KPV? The Tripeptide From Alpha-MSHKPV is Lys-Pro-Val, the C-terminal tripeptide of alpha-MSH, at 342.43 Da. It carries reported anti-inflammatory activity without the pigmentation effects.
- Alpha-MSH: Pigmentation and Inflammation in One HormoneA 13-residue hormone doing two unrelated jobs. Why separating its anti-inflammatory C-terminus from its pigmentation activity was worth attempting.
- How KPV Is Reported to ActReported effects centre on NF-kB signalling and pro-inflammatory cytokine production. Why the mechanism is described intracellularly rather than at a receptor.
- KPV Structure and Physical PropertiesThree residues, 342.43 Da, one proline and one lysine. What a tripeptide can and cannot do structurally, and why analysis is difficult.
- KPV Chemical IdentitySearching PubChem for KPV returns an unrelated organic acid. The peptide is indexed as Lys-Pro-Val, CID 125672, 342.43 Da.